WhiteHawk Capital Partners, a private credit investment manager focused on asset-based financing solutions, entered into an agreement with Nephron Pharmaceuticals, a provider of generic respiratory and 503B outsourcing medications with expertise in sterile dose medications and compounded solutions, to provide a $350 million asset-based credit facility. Nephron will use proceeds of the financing to support a recapitalization and liquidity for continued growth.
“Nephron is pleased to collaborate with WhiteHawk as we embark on an exciting journey of growth and innovation in 2025,” Lou Kennedy, co-owner and CEO of Nephron, said. “Our recapitalization marks a pivotal step in our commitment to setting new standards for excellence in the industry.”
“Nephron is on an impressive growth trajectory, solidifying its position as a premier provider of essential pharmaceuticals to wholesalers, retailers, and hospitals across the nation,” Rob Chimenti, managing director at WhiteHawk, said. “We are proud to partner with a company that not only delivers life-saving products but also plays a crucial role in addressing drug shortages and ultimately strengthening the resilience of our overall healthcare system.”
